Plasma glycated CD59, detectable via a sensitive and specific enzyme-linked immunosorbent assay [73], has been suggested as a promising diagnostic [73,74,75,76,77] and predictive [78] biomarker of type 2 diabetes [73], pregnancy-induced glucose intolerance [74], gestational diabetes [75,76,77,78], and postpartum glucose intolerance [79,80]. Here, CD59 is linked to Glucose intolerance.